Award
National Cancer Institute 5R01CA262420-04
SLC6A14 as a unique drug target to treat pancreatic cancer
Recipient
Texas Tech University Health Sciences Center
Award Amount
$349,640.00
Ceiling
$349,640.00
Awarded
April 10, 2026
Identifier
5R01CA262420-04
Research project funded by the National Cancer Institute to study SLC6A14 as a drug target for pancreatic cancer, including testing combination therapies to improve treatment efficacy.
Description
The project aims to evaluate SLC6A14 as a drug target for pancreatic ductal adenocarcinoma (PDAC), characterize autophagy and macropinocytosis induced by SLC6A14 inactivation, and test combination therapies targeting SLC6A14 and autophagy/macropinocytosis to improve therapeutic outcomes. The study involves genetic deletion and pharmacological blockade of SLC6A14 in mouse models and human cell lines, with the goal of developing more effective treatments.